KR101150250B1 - 시스-ｆｔｃ의 다형 및 기타 결정형 - Google Patents

시스-ｆｔｃ의 다형 및 기타 결정형 Download PDF

Info

Publication number
KR101150250B1
KR101150250B1 KR1020107016624A KR20107016624A KR101150250B1 KR 101150250 B1 KR101150250 B1 KR 101150250B1 KR 1020107016624 A KR1020107016624 A KR 1020107016624A KR 20107016624 A KR20107016624 A KR 20107016624A KR 101150250 B1 KR101150250 B1 KR 101150250B1
Authority
KR
South Korea
Prior art keywords
ftc
cis
iii
forms
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107016624A
Other languages
English (en)
Korean (ko)
Other versions
KR20100091265A (ko
Inventor
케니스 알. 페어스
드발리나 로
유에롱 후
Original Assignee
아보트 래버러토리즈
길리애드 사이언시즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아보트 래버러토리즈, 길리애드 사이언시즈, 인코포레이티드 filed Critical 아보트 래버러토리즈
Publication of KR20100091265A publication Critical patent/KR20100091265A/ko
Application granted granted Critical
Publication of KR101150250B1 publication Critical patent/KR101150250B1/ko
Assigned to 애브비 인코포레이티드 reassignment 애브비 인코포레이티드 권리지분의 전부이전등록 Assignors: 아보트 래버러토리즈
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020107016624A 2001-03-01 2002-03-01 시스-ｆｔｃ의 다형 및 기타 결정형 Expired - Fee Related KR101150250B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27256001P 2001-03-01 2001-03-01
US60/272,560 2001-03-01
US30960501P 2001-08-02 2001-08-02
US60/309,605 2001-08-02
PCT/US2002/006184 WO2002070518A1 (en) 2001-03-01 2002-03-01 Polymorphic and other crystalline forms of cis-ftc

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020087016002A Division KR101015510B1 (ko) 2001-03-01 2002-03-01 시스-ｆｔｃ의 다형 및 기타 결정형

Publications (2)

Publication Number Publication Date
KR20100091265A KR20100091265A (ko) 2010-08-18
KR101150250B1 true KR101150250B1 (ko) 2012-06-12

Family

ID=26955597

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020107016624A Expired - Fee Related KR101150250B1 (ko) 2001-03-01 2002-03-01 시스-ｆｔｃ의 다형 및 기타 결정형
KR1020087016003A Expired - Fee Related KR100927024B1 (ko) 2001-03-01 2002-03-01 시스-ｆｔｃ의 다형 및 기타 결정형
KR10-2003-7011355A Ceased KR20040002871A (ko) 2001-03-01 2002-03-01 시스-ｆｔｃ의 다형 및 기타 결정형
KR1020087016002A Expired - Fee Related KR101015510B1 (ko) 2001-03-01 2002-03-01 시스-ｆｔｃ의 다형 및 기타 결정형

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020087016003A Expired - Fee Related KR100927024B1 (ko) 2001-03-01 2002-03-01 시스-ｆｔｃ의 다형 및 기타 결정형
KR10-2003-7011355A Ceased KR20040002871A (ko) 2001-03-01 2002-03-01 시스-ｆｔｃ의 다형 및 기타 결정형
KR1020087016002A Expired - Fee Related KR101015510B1 (ko) 2001-03-01 2002-03-01 시스-ｆｔｃ의 다형 및 기타 결정형

Country Status (14)

Country Link
US (3) US6723728B2 (https=)
EP (3) EP1574512B1 (https=)
JP (4) JP5105689B2 (https=)
KR (4) KR101150250B1 (https=)
CN (4) CN102911165B (https=)
AT (2) ATE312097T1 (https=)
AU (1) AU2002335489B2 (https=)
CA (4) CA2439831C (https=)
CY (2) CY1107983T1 (https=)
DE (2) DE60207850T2 (https=)
DK (2) DK1389207T3 (https=)
ES (3) ES2537007T3 (https=)
PT (2) PT1903041E (https=)
WO (1) WO2002070518A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101150250B1 (ko) * 2001-03-01 2012-06-12 아보트 래버러토리즈 시스-ｆｔｃ의 다형 및 기타 결정형
TWI244393B (en) * 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
MXPA05007016A (es) 2003-01-14 2005-09-12 Gilead Sciences Inc Composiciones y metodos para terapia antiviral de combinacion.
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US20060014949A1 (en) * 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
WO2009005338A2 (en) * 2007-07-05 2009-01-08 Ultimorphix Technologies B.V. Solid forms ult-i, ult-2 and ult-3 of emtricitabine
EP2350065A1 (en) 2008-11-12 2011-08-03 Lupin Ltd. A novel polymorph of emtricitabine and a process for preparing of the same
EP2454244B1 (en) 2009-07-15 2013-06-26 Lupin Limited An improved process for preparation of efavirenz

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210085A (en) * 1990-02-01 1993-05-11 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4476248A (en) 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen
US5684153A (en) 1984-08-16 1997-11-04 Beecham Group Plc Process for the preparation of purine derivatives
DE3485225D1 (de) 1983-08-18 1991-12-05 Beecham Group Plc Antivirale guanin-derivate.
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
AU2526188A (en) 1987-09-22 1989-04-18 Regents Of The University Of California, The Liposomal nucleoside analogues for treating aids
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5684164A (en) * 1988-04-11 1997-11-04 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5041449A (en) 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
NZ228645A (en) 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US6703396B1 (en) * 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5827727A (en) * 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5700937A (en) 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
AU7872491A (en) 1990-05-07 1991-11-27 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
EP0531452A4 (en) 1990-05-29 1993-06-09 Vical, Inc. Synthesis of glycerol di- and triphosphate derivatives
ATE131825T1 (de) 1990-06-13 1996-01-15 Arnold Glazier Phosphorylierte prodrugs
US5674849A (en) 1990-10-24 1997-10-07 Allelix Biopharmaceuticals Inc. Anti-viral compositions
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US6228860B1 (en) * 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
US5444063A (en) 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5179104A (en) 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ241625A (en) * 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
GB9104740D0 (en) 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
IT1244501B (it) 1991-03-22 1994-07-15 Sigma Tau Ind Farmaceuti Derivati amminoacilici e oligopeptidici dell'allopurinolo dotati di attivita' immunostimolante e composizioni farmaceutiche che li contengono
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
AU668873B2 (en) 1991-07-12 1996-05-23 Chimerix, Inc. Antiviral liponucleosides: treatment of hepatitis B
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
EP0746319A4 (en) 1993-05-12 1997-11-05 Karl Y Hostetler ACYCLOVIR DERIVATIVES FOR TOPICAL USE
GB9311709D0 (en) 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
US5808040A (en) 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
SE9500872L (sv) * 1995-03-10 1996-04-01 Tony Wiseby Anordning vid sikte för pilbåge
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
DE19543707A1 (de) * 1995-11-23 1997-05-28 Inst Neue Mat Gemein Gmbh Verfahren zum Konservieren von Papier
GB9525606D0 (en) 1995-12-14 1996-02-14 Iaf Biochem Int Method and compositions for the synthesis of dioxolane nucleosides with › - configuration
AU5127098A (en) 1996-11-29 1998-06-22 Smithkline Beecham Plc Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis
TW318283B (en) 1996-12-09 1997-10-21 United Microelectronics Corp Multi-level read only memory structure and manufacturing method thereof
ATE267198T1 (de) 1997-03-19 2004-06-15 Univ Emory Synthese und anti-hiv und anti-hepatitis virus aktivität von 1,3-oxaselenolan nucleosiden
CA2340214C (en) * 1998-08-12 2007-10-30 Triangle Pharmaceuticals, Inc. Method of manufacture of 1,3-oxathiolane nucleosides
AU773127B2 (en) 1998-10-09 2004-05-20 Altus Pharmaceuticals, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
KR101150250B1 (ko) * 2001-03-01 2012-06-12 아보트 래버러토리즈 시스-ｆｔｃ의 다형 및 기타 결정형
US6600044B2 (en) * 2001-06-18 2003-07-29 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210085A (en) * 1990-02-01 1993-05-11 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds

Also Published As

Publication number Publication date
US7544692B2 (en) 2009-06-09
AU2002335489B2 (en) 2008-06-05
CN102911166A (zh) 2013-02-06
KR20080065317A (ko) 2008-07-11
PT1574512E (pt) 2008-03-05
US20090306114A1 (en) 2009-12-10
US20050026934A1 (en) 2005-02-03
KR20040002871A (ko) 2004-01-07
CY1107913T1 (el) 2013-09-04
JP5105689B2 (ja) 2012-12-26
ATE383355T1 (de) 2008-01-15
DK1574512T3 (da) 2008-03-03
DE60207850T2 (de) 2006-08-10
CA2788498A1 (en) 2002-09-12
CN1503796B (zh) 2012-07-04
EP1903041A3 (en) 2008-04-23
KR101015510B1 (ko) 2011-02-16
ATE312097T1 (de) 2005-12-15
CA2690137C (en) 2012-11-13
CN102911165B (zh) 2016-08-17
CY1107983T1 (el) 2013-09-04
CA2439831A1 (en) 2002-09-12
CA2439831C (en) 2010-01-12
ES2299950T3 (es) 2008-06-01
EP1389207A1 (en) 2004-02-18
US6723728B2 (en) 2004-04-20
JP2013040192A (ja) 2013-02-28
KR100927024B1 (ko) 2009-11-17
CN102911165A (zh) 2013-02-06
DE60224592D1 (de) 2008-02-21
ES2253544T3 (es) 2006-06-01
US8637535B2 (en) 2014-01-28
CN1503796A (zh) 2004-06-09
DE60224592T2 (de) 2009-01-29
ES2537007T3 (es) 2015-06-01
DK1389207T3 (da) 2006-04-18
EP1574512B1 (en) 2008-01-09
CA2690137A1 (en) 2002-09-12
US20030060645A1 (en) 2003-03-27
KR20100091265A (ko) 2010-08-18
DE60207850D1 (de) 2006-01-12
CA2867970A1 (en) 2002-09-12
CA2788498C (en) 2016-02-16
EP1574512A1 (en) 2005-09-14
JP2004530660A (ja) 2004-10-07
CN102911166B (zh) 2016-08-17
EP1389207B1 (en) 2005-12-07
JP2009197005A (ja) 2009-09-03
PT1903041E (pt) 2015-06-23
WO2002070518A1 (en) 2002-09-12
KR20080065316A (ko) 2008-07-11
EP1903041A2 (en) 2008-03-26
CN102942563A (zh) 2013-02-27
EP1903041B1 (en) 2015-02-18
JP2015028045A (ja) 2015-02-12

Similar Documents

Publication Publication Date Title
US8637535B2 (en) Polymorphic and other crystalline forms of cis-FTC
US20030176319A1 (en) N4-acylcytosine-1,3- dioxolane nucleosides for treatment of viral infections
EP2007758A1 (en) A novel crystalline form of lamivudine
AU2002335489A1 (en) Polymorphic and other crystalline forms of cis-FTC
CN101918394A (zh) 制备取代的1,3-氧硫杂环戊烷的方法
AU2008202336B2 (en) Polymorphic and other crystalline forms of cis-FTC

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20150518

Year of fee payment: 4

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20160418

Year of fee payment: 5

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20170421

Year of fee payment: 6

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20180502

Year of fee payment: 7

PR1001 Payment of annual fee

Fee payment year number: 7

St.27 status event code: A-4-4-U10-U11-oth-PR1001

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20190522

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190522

St.27 status event code: N-4-6-H10-H13-oth-PC1903

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000